{"preliminary_commentary":{"by_channel":{"x_thread":21,"youtube":10,"podcast":4,"bluesky_thread":1,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03191786\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"IPSOS","nct_id":"NCT03191786","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ipsos-nct03191786. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IPSOS","arms":[{"description":"Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death.","label":"Atezolizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive single agent chemotherapy; either vinorelbine oral or IV, or gemcitabine IV, according to the label based on investigator's choice.","label":"Single Agent Chemotherapy (Vinorelbine or Gemcitabine)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2023-10-25","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":453,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody","otherNames":["MPDL3280A"],"type":"DRUG"},{"name":"Vinorelbine","otherNames":["Navelbine®"],"type":"DRUG"},{"name":"Gemcitabine","otherNames":["Gemzar®"],"type":"DRUG"}],"last_update":"2024-10-23","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent (Stage IIIb Not Amenable for Multimodality Treatment) or Metastatic (Stage IV) Non-Small Cell Lung Cancer Who Are Deemed Unsuitable for Platinum-Containing Therapy","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-04-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"From randomization up to death from any cause (up to approximately 55 months)"}],"references":[{"citation":"Han B, Peters S, Le AT, Huang D, Wu G, Cao L, Pham CP, Zhao J, Wang K, Yang N, Zhong H, Hu Y, Morris S, Lam V, Graupner V, Gitlitz B, Hoglander E, Schulz C, Lee SM. First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation. Chin Med J (Engl). 2026 Jun 20;139(12):1838-1845. doi: 10.1097/CM9.0000000000003796. Epub 2025 Dec 17.","pmid":"41424028","type":"DERIVED"},{"citation":"Peters S, Schulz C, Reck M, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Contreras JR, Palmero R, Mak MP, Popat S, Hu Y, Morris S, Srivastava MK, Kaul M, Graupner V, Gitlitz B, Lee SM. Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study. J Thorac Oncol. 2025 Dec;20(12):1843-1850. doi: 10.1016/j.jtho.2025.07.115. Epub 2025 Jul 22.","pmid":"40706710","type":"DERIVED"},{"citation":"Li B, Rong D, Lin H. Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA. BMJ Open. 2024 Nov 12;14(11):e083716. doi: 10.1136/bmjopen-2023-083716.","pmid":"39532375","type":"DERIVED"},{"citation":"Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Hoglander E, Connors M, Biggane AM, Vollan HK, Peters S. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study. Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6.","pmid":"37423228","type":"DERIVED"},{"citation":"Gijtenbeek RG, de Jong K, Venmans BJ, van Vollenhoven FH, Ten Brinke A, Van der Wekken AJ, van Geffen WH. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. Cochrane Database Syst Rev. 2023 Jul 7;7(7):CD013382. doi: 10.1002/14651858.CD013382.pub2.","pmid":"37419867","type":"DERIVED"}],"start_date":{"date":"2017-09-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy","url":"https://clinicaltrials.gov/study/NCT03191786"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ipsos-nct03191786"}